APPENDIX OF AMENDED ABSTRACT
Followed by
Substitute Page 11

AM100123

EQUINE PROTOZOAL MYELOENCEPHALITIS VACCINE

ABSTRACT OF THE INVENTION

The present invention provides an immunogenically active component comprising inactivated *Sarcocystis neurona* cells and/or inactivated *Neospora hughesi* cells; antigens derived therefrom; DNA derived therefrom; or a mixture; or in combination with other vaccine components thereof. Further provided are vaccine compositions useful for preventing or ameliorating equine protozoal myeloencephalitis infection and disease and a method for the cell culture propagation of protozoan parasites.

$1x10^4$ inactivated *Sarcocystis* Spp. cells or *Neospora* Spp. cells or a mixture thereof, preferably at least about $1x10^6$ cells, are suitable.

As used in the specification and claims, the term "immunogenically stimulating adjuvant" designates a compound which is capable of potentiating or stimulating the immune response in a subject animal when administered in combination with the immunogenically active component of the invention. Examples of an immunogenically stimulating adjuvant suitable for use in the vaccine composition of the invention include: surfactants such as hexadecylamine, octadecylamine, lysolecithin, dimethyl dioctadicyl ammonium bromide, N,N-dioctadecyl-N'-N-bis(2-hydroxyethyl-propane diamine), methoxyhexadecylglycerol, polyoxyethylene-polyoxypropylene block copolymer (e.g.,PLURONIC® polyols), saponin, Quil® A, or the like; polyanions such as pyran, dextran sulfate, polynucleotide complex of polyinosinicpolycytidylic acid, polyacrylic acid, carboxypolymethylenes and carboxyvinyl polymers such as CARBOPOL®, aluminum hydroxide, aluminum phosphate, or the like; peptides such as muramyl dipeptide, dimethyl glycine, tuftsin or the like; oil emulsions; immunomodulators such as interleukin-1, interleukin-2, interleukin-12, GM-CSF or the like; or a combination thereof. A preferred immunogenically stimulating adjuvant suitable for use in the vaccine composition of the invention is a mixture of squalane and a polyoxyethylene-polyoxypropylene block copolymer (e.g., Pluronic® L121, BASF, Parsippany, NJ) capable of forming small liposomes. The immunogenically stimulating adjuvant may be present in the vaccine composition of the